MedTrace Logo

WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise

NCT06576050 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2024-09-04

No results posted yet for this study

Summary

The goal of this study is to define how treatment of obesity impacts cardiometabolic performance during exercise in patients with established HFpEF or at risk for HFpEF. Multi-dimensional physical activity, including 6 minute walk distance, resting metabolic rate, the metabolic cost of initiating exercise, and low-level, intermediate, peak exercise, and recovery oxygen utilization patterns will be examined in relation to weight loss in people having bariatric surgery. The investigators also aim to learn more about the relationship between obesity, exercise intolerance, and heart failure with preserved ejection fraction (HFpEF). The investigators are interested in the extent to which HFpEF\'s manifestations are preventable or reversible with weight-loss interventions. The main questions it aims to answer are:

1. How does weight loss surgery affect comprehensive measures of physical activity?
2. What are the biochemical signatures of obesity and their reversibility in patients with HFpEF and obesity?

Conditions

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-25
Primary Completion
2024-08-02
Completion
2024-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06576050 on ClinicalTrials.gov